Target intelligence / Profile preview

Hypoxia-inducible factor 1-alpha inhibitor (FIH-1) (FIH-1)

Target
FIH-1
Molecular classification
Enzyme, 2-oxoglutarate-dependent dioxygenase, Asparaginyl hydroxylase
01

Overview

Hypoxia-inducible factor 1-alpha inhibitor (FIH-1), encoded by the HIF1AN gene, is a Fe(II)- and 2-oxoglutarate-dependent asparaginyl hydroxylase that serves as a critical oxygen sensor in mammalian cells (UniProt, 2024). It regulates the transcriptional activity of hypoxia-inducible factors (HIFs) by hydroxylating a specific asparagine residue (Asp803 in HIF-1α) within their C-terminal transactivation domain (CAD). This hydroxylation sterically blocks the interaction between HIF and its transcriptional co-activators, p300 and CBP, effectively silencing the hypoxic gene expression program under normoxic conditions (Lando et al., 2002). Unlike prolyl hydroxylases (PHDs) that target HIF for degradation, FIH-1 has a higher affinity for oxygen, allowing it to function as a fine-tuner of the hypoxic response at intermediate oxygen levels (Hewitson et al., 2002). In clinical research, FIH-1 is a target of interest for treating ischemic diseases, anemia, and metabolic disorders, as its inhibition can enhance the adaptive response to low oxygen (Wilkins et al., 2016). However, therapeutic development faces challenges regarding the selectivity of inhibitors and the potential risk of promoting tumor-supportive pathways like angiogenesis and glycolysis (Zhang et al., 2010).

Other names
HIF1ANFactor inhibiting HIF-1Asparaginyl hydroxylase FIH1Peptide-aspartate (asparagine) dioxygenase
02

Mechanism of action

Inhibition of asparaginyl hydroxylase activity to prevent HIF-1α CAD hydroxylation, thereby promoting p300/CBP recruitment and HIF-mediated transcription (Lando et al., 2002; Wilkins et al., 2016).

03

Biological functions

Oxygen sensingRegulation of transcriptionProtein hydroxylationNegative regulation of HIF-1 activity
04

Disease associations

CancerIschemiaAnemiaMetabolic disorderCardiovascular disease
05

Safety considerations

Oncogenic potential due to HIF activationOff-target inhibition of other 2-OG dioxygenasesMetabolic dysregulationPotential developmental toxicityInterference with Notch signaling pathways
06

Interacting drugs

Dimethyloxalylglycine (DMOG)

4 more in the full profile.

07

Biomarkers

HIF-1α Asp803 hydroxylation statusErythropoietin (EPO) levelsVascular endothelial growth factor (VEGF) levels

Beyond the preview

Go deeper on Hypoxia-inducible factor 1-alpha inhibitor (FIH-1) (FIH-1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hypoxia-inducible factor 1-alpha inhibitor (FIH-1) (FIH-1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call